Standardized Definition for Structural Valve Degeneration Summary

The VIVID (Valve-in-Valve International Data) group have published a standardised set of definitions for structural valve degeneration (SVD) of surgical and transcatheter aortic valve bioprostheses. They also make recommendations for the timing of clinical and imaging follow-up.

Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG, et al. Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation. 2018 Jan 23;137(4):388–99.

 

Definition

  • An acquired intrinsic bioprosthetic valve abnormality defined as deterioration of the leaflets or supporting structures
  • Resulting in thickening, calcification, tearing, or disruption of the prosthetic valve materials with eventual associated valve hemodynamic dysfunction
  • Is caused by tissue disruption or thickening over time because of mechanical stress + abnormal flow shear stress
  • SVD does NOT include patient-prosthesis mismatch, device malposition, paravalvular regurgitation, & abnormal frame expansion
  • The process is usually gradual (over years) and so has been divided into stage

 Echocardiographic Assessment

 

Clinical Application

  • Routine post-procedural anticoagulation is currently a IIa recommendation for 3 months post SAVR
  • If a change in mean gradient > 10 mmHg or a clinical event (stroke, heart failure, decreased EF, new PVL) then 4D CT or TOE should be done
    • If leaflets are thickened should consider a trial of anticoagulation
  • All patients diagnosed with SVD should undergo a repeat TTE within 3 to 6 months to evaluate for rapid progression
  • For symptomatic patients with severe AR or AS, or moderate mixed AS/AR, should be considered for redo SAVR or valve-in-valve TAVR

 

About The Author

Michael Seco

Dr Michael Seco is a Cardiothoracic Surgery Registrar at Royal Prince Alfred Hospital, Sydney, Australia. He has research interests in minimally invasive adult cardiac surgical techniques, including robotic-assisted coronary artery bypass grafting, transcatheter aortic valve implantation, and off-pump surgery. Dr Seco also builds and develops large scale databases used to perform clinical studies.

SHDA is supported by

Recent Tweets

Subscribe

Upcoming Meetings

august

02augAll Day05Cardiac Society of Australia & New Zealand (CSANZ) 66th Annual Scientific MeetingCSANZ 2018

03augAll Day05Australia & New Zealand Endovascular Therapies (ANZET) Meeting 2018ANZET 2018

25augAll Day29European Society of Cardiology (ESC) Congress 2018ESC 2018

october

05octAll Day06Cardiac Thoracic Vascular & Perfusion (CTVP) Special Interest Group Meeting 2018CTVP SIG 2018

10octAll Day12Featured17th Echo Australia Conference, SydneyEcho Australia 2018

18octAll Day20Pulmonary Hypertension Society of Australia & New Zealand (PHSANZ) ASM

X